AU2010232407B2 — Feedback systems and methods to enhance obstructive and other obesity treatments
Assigned to IntraPace Inc · Expires 2014-10-30 · 12y expired
What this patent protects
Feedback systems and methods enhance obstructive and other obesity treatments by presenting feedback regarding patients' actual eating and/or exercise habits. An ingestion restricting implant body can be deployed along the gastrointestinal tract. In some embodiments, ingestion al…
USPTO Abstract
Feedback systems and methods enhance obstructive and other obesity treatments by presenting feedback regarding patients' actual eating and/or exercise habits. An ingestion restricting implant body can be deployed along the gastrointestinal tract. In some embodiments, ingestion alters the implant body, which, in turn, generates signals. The generated signals can be used to inhibit unhealthy ingestion by the patient. In other embodiments, the implant body can be altered by signals so as to selectable change the restriction imposed on the gastrointestinal tract, optionally in response to ingestion events, an eating schedule, or the like. The implant body may comprise a gastric band or an intragastric balloon. Sensor signals may be processed to identify ingestion and/or characterize ingestion of a solid or a liquid, and the results may be displayed on a screen for a patient or coach to view.
Drugs covered by this patent
- Abilify (aripiprazole) · Generic (originally Otsuka/BMS)
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.